Equities

ImmuPharma PLC

IMM:LSE

ImmuPharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)6.38
  • Today's Change-0.13 / -2.00%
  • Shares traded2.21m
  • 1 Year change63.59%
  • Beta6.5813
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Profile data is unavailable for this security.

About the company

ImmuPharma PLC is a specialist drug discovery and development company. The Company is engaged in the development of drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases with high medical need. Its lead program, P140, is a non-immunosuppressing, convenient and safe peptide treatment for autoimmune disease, which is in late-stage development for the treatment of systemic lupus erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB is an advanced anti-infective candidate. It is an improved form of amphotericin-B (AMB), a systemic antifungal drug. BioCin is an improved form of vancomycin, a systemic antibacterial which is highly effective against Methicillin-resistant Staphylococcus Aureus (MRSA) and orally against Clostridium Difficile infections.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-3.93m
  • Incorporated2000
  • Employees6.00
  • Location
    ImmuPharma PLCOne Bartholomew CloseLONDON EC1A 7BLUnited KingdomGBR
  • Phone+44 20 7152 4080Fax+44 20 7152 4001
  • Websitehttps://www.immupharma.co.uk/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Futura Medical PLC7.93m-6.29m7.41m12.007.41m12.00
OptiBiotix Health PLC1.15m-191.00k7.90m5.007.90m5.00
IXICO PLC6.53m-1.65m9.50m79.009.50m79.00
Genflow Biosciences PLC0.00-1.80m10.36m5.0010.36m5.00
Solvonis Therapeutics PLC0.00-2.60m17.02m--17.02m--
Fusion Antibodies PLC1.60m-1.47m20.00m24.0020.00m24.00
Sareum Holdings Plc0.00-4.44m23.47m5.0023.47m5.00
Arecor Therapeutics PLC5.06m-8.10m29.26m37.0029.26m37.00
Poolbeg Pharma PLC0.00-5.71m32.07m10.0032.07m10.00
ImmuPharma PLC0.00-3.93m32.07m6.0032.07m6.00
hVIVO PLC51.28m5.28m41.91m301.0041.91m301.00
Skinbiotherapeutics PLC4.64m-696.25k52.43m41.0052.43m41.00
Data as of Feb 06 2026. Currency figures normalised to ImmuPharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

23.11%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Fund Managers Ltd.as of 01 Dec 202531.03m6.17%
IG Markets Ltd.as of 01 Dec 202529.88m5.94%
HSBC Global Asset Management (UK) Ltd.as of 01 Dec 202529.78m5.92%
KW Investment Management Ltd.as of 01 Dec 202513.26m2.64%
iDealing.com Ltd.as of 01 Dec 20253.93m0.78%
Bank J. Safra Sarasin AG (Investment Management)as of 01 Dec 20252.57m0.51%
Aviva Investors Global Services Ltd.as of 20 Apr 20182.09m0.42%
UBS Asset Management Switzerland AGas of 01 Dec 20251.55m0.31%
TrinityBridge Ltd.as of 01 Dec 20251.15m0.23%
BLI - Banque de Luxembourg Investments SAas of 01 Dec 2025948.00k0.19%
More ▼
Data from 31 Mar 2025 - 02 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.